Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Sanofi Oncology Business Unit Head Pascal Rigaudy to Become New President of Genzyme Japan
Genzyme Japan, a member of Sanofi Group, announced on May 27 that Pascal Rigaudy, corporate officer and head of the oncology business unit at Sanofi K.K., will take the helm at the company as its new representative director and president…
To read the full story
BUSINESS
- Japan Ethical Drug Sales Rise 7.3% in April: Crecon
June 8, 2026
- Takeda Swings to Loss after Booking Amitiza Litigation Charge
June 8, 2026
- Eisai to Raise 50 Billion Yen via Bond Issue for R&D, Licensing
June 5, 2026
- Japan Market for Fertility, Contraception, Female Disorders Put at 228.5 Billion Yen by FY2035
June 5, 2026
- Toho, DHL Partner on Healthcare Logistics Platform
June 5, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…